Welcome to our dedicated page for GLOBUS MEDICAL news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on GLOBUS MEDICAL stock.
Globus Medical Inc. (NYSE: GMED) is a leading manufacturer of musculoskeletal implants and a pioneer in advancing spinal surgery through technological innovations. Founded in 2003, the company is renowned for its commitment to improving the quality of life for patients suffering from spinal disorders. With a focus on superior engineering and technology, Globus Medical offers a comprehensive suite of spinal products designed to facilitate pain-free, active living.
Globus Medical's product portfolio is divided into two main categories:
- Musculoskeletal Solutions: This segment includes an array of medical devices and instruments primarily used for spinal and orthopedic procedures. These products are the primary revenue drivers for the company, with a significant portion of sales generated within the United States.
- Enabling Technologies: This category features advanced computer systems developed to enhance surgical capabilities, providing surgeons with innovative tools to improve patient outcomes.
The company's dedication to innovation has made it the fastest-growing entity in the history of orthopedics. Recent achievements highlight this growth trajectory. Globus Medical announced an increase in its full-year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, with non-GAAP fully diluted earnings per share reaffirmed at $2.30. Looking ahead, the company has updated its full-year 2024 revenue guidance to a range of $2.460 billion to $2.485 billion and non-GAAP fully diluted earnings per share between $2.75 and $2.85.
Globus Medical continues to foster strong partnerships and engage in cutting-edge projects aimed at expanding its market presence and technological capabilities. The company's headquarters are located in Audubon, PA, and it remains actively involved in the medical community through participation in teleconferences, investor calls, and industry events.
For more information about their latest products, financial performance, and upcoming events, you can visit the Globus Medical website at www.globusmedical.com.
Globus Medical (NYSE: GMED) announced its financial results for Q4 and full year 2022, reporting worldwide net sales of $274.5 million for Q4, a 9.8% increase year-over-year, and $1,022.8 million for the full year, a 6.8% rise. GAAP net income for Q4 soared to $50.1 million, a 231.4% increase from the prior year, while diluted EPS was $0.49. The company achieved non-GAAP diluted EPS of $0.59. Free cash flow for 2022 reached $104.4 million, with no debt reported. Looking ahead, Globus forecasts 2023 net sales of $1.1 billion and non-GAAP diluted EPS of $2.30.
The merger between Globus Medical (GMED) and NuVasive (NUVA) will form a leading musculoskeletal technology company, enhancing innovation in patient care. Under the all-stock agreement, NuVasive shareholders will receive 0.75 shares of Globus Medical for each share held, implying a price of $57.72 and an equity value of $3.1 billion. The new entity aims to capitalize on a $50 billion market, with combined net sales growth projected at 6-8% for 2023. This transaction is expected to close mid-2023, pending regulatory and shareholder approval.
Globus Medical (NYSE:GMED) will announce its financial results for Q4 and full year ended December 31, 2022, after market close on February 21, 2023. Investors can access the release on the company's website. A teleconference will be held at 4:30 p.m. ET to discuss the results, with live access available through the Investors page. Participants can join via telephone after pre-registration. Globus Medical is recognized for its musculoskeletal solutions, focused on enhancing surgical outcomes. Further information about their products and initiatives can be found on their website.
Globus Medical, a leader in musculoskeletal solutions, reported Q3 2022 financial results with worldwide net sales of $254.1 million, marking a 10.6% increase year-over-year. U.S. net sales rose by 9.5%, and international sales surged by 17.7%. GAAP net income was $47.4 million, a 0.5% increase, with diluted EPS at $0.47. The company reaffirmed its full-year guidance of $1.025 billion in sales but lowered non-GAAP diluted EPS guidance to $2.03 due to unfavorable currency impacts. The company remains debt-free.
Globus Medical (NYSE:GMED) will announce its Q3 2022 financial results on November 8, 2022, after market close. A teleconference is scheduled for the same day at 4:30 PM ET, accessible via the company's investor website. This release will provide insights into the company's financial performance for the quarter ending September 30, 2022. Shareholders can listen to the live call and will have access to an audio archive afterward. For more details, visit the Globus Medical investor page.
Globus Medical reported its Q2 2022 financial results, achieving worldwide net sales of $263.6 million, a 5.0% increase year-over-year, with a 6.5% rise on a constant currency basis. GAAP net income rose to $54.6 million, a 31.4% increase from Q2 2021, with diluted EPS at $0.53. Notably, the Enabling Technologies sector saw a 41.7% growth to $29.4 million, fueled by strong demand for robotic systems. The company reaffirms its 2022 guidance of $1.025 billion in net sales and $2.10 non-GAAP diluted EPS.
Globus Medical (NYSE:GMED) will announce its second-quarter financial results for the period ending June 30, 2022, after market close on August 4, 2022. Investors can access the release on their website. A teleconference will be held the same day at 4:30 p.m. Eastern Time to discuss the performance with stakeholders. Interested participants can join via a webcast or telephone by pre-registering for access. The audio archive will be available post-call. Globus Medical specializes in musculoskeletal solutions and was founded in 2003.
Globus Medical (NYSE: GMED) announced the successful first surgeries using the Excelsius3D™ imaging platform, enhancing its existing ExcelsiusGPS® robotic navigation system. Surgeons from various hospitals performed these surgeries, highlighting the system's capabilities for minimally invasive procedures and improved surgical outcomes. The Excelsius3D™ provides a streamlined navigation workflow, offers multiple imaging modes, and reduces radiation exposure. This technology is now commercially available in the US, aiming to elevate patient care in spinal surgeries.
Globus Medical (NYSE: GMED) reported Q1 2022 financial results, with worldwide net sales of $230.5 million, a 1.4% year-over-year increase. GAAP net income was $38.1 million, reflecting a 16.0% decrease from the previous year, attributed to higher product development and marketing expenses. Diluted EPS stood at $0.37, down 13.1% from $0.44. The company reaffirmed its 2022 guidance, targeting $1.025 billion in net sales. Notably, U.S. Spine sales showed recovery, with record performance in March.
Globus Medical (NYSE:GMED) is set to release its financial results for Q1 ended March 31, 2022, on May 10, 2022, after market close. Investors can access the release on the company’s website, where a teleconference will follow at 4:30 p.m. ET to discuss performance with the investment community. Interested parties can join the call via phone or access it online. The company specializes in musculoskeletal solutions, aiming to enhance surgical outcomes.
FAQ
What is the current stock price of GLOBUS MEDICAL (GMED)?
What is the market cap of GLOBUS MEDICAL (GMED)?
What does Globus Medical Inc. specialize in?
When was Globus Medical Inc. founded?
What are the main product categories of Globus Medical?
Where is Globus Medical Inc. headquartered?
How can I access the latest financial results of Globus Medical?
What is the company's revenue guidance for the fiscal year 2024?
How does Globus Medical contribute to spinal surgery advancements?
What percentage of Globus Medical's revenue comes from the United States?
How can investors participate in Globus Medical’s teleconference calls?
Where can I find more information about Globus Medical's products and services?
